	CRF 01 -	CONFIRMAT	ION OF ELIGIE	BILITY AND STUDY EN	TRY	FC	RN	l				
PIPS2	Site ID:		Area:	Patient's Initials:								
	Patient ID:			Patient's DoB:	D	D	Μ	Μ	Y	Y	Y	Y

Please answer by ticking the appropriate box or filling in the required information.

1. INCLUSION CRITERIA: If any of the below criteria is answered NO, the participant is	s NOT eligible for the	e trial.								
Has the patient been recently referred (or re-referred) service?	to palliative care	Yes 🗌	No 🗆							
Has the patient locally advanced or metastatic, incurable* cancer? Yes No [* Incurable means that the disease cannot be eradicated and the estimated survival is less than one year.										
Is the patient aged 18 years or over?		Yes 🗌	No 🗆							
Has the patient sufficient English language skills?		Yes 🗌	No 🗆							
2. EXCLUSION CRITERION: If the criterion below is answered YES, the participant is NO	T eligible for the tria	μ.								
Currently receiving (or planned to receive) treatment with curative intent?										
 Capacity If capacity is unclear then please complete a four point capa Royal College of General Practitioners' MCA Toolkit worksh 			on the							
Has the patient the capacity to consent to participate in the	ne study?	Yes 🗌	No 🗆							
4a. CONSENT If patient has capacity, 'YES' in 3:										
Has the patient provided written consent?		Yes 🗌	No 🗆							
4b. CONSENT If patient doesn't have capacity, 'NO' in 3:										
Has a signed declaration form been received from a personal or nominated consultee?	Yes, personal co Yes, nominated		No 🗆							

0	Completed by		Con	nplet	ed or	ı				
Clinical Trials Unit	Print Name	Signature	D	D	M	Μ	Y	Y	Y	Y

PiPS2 CRF 01 Confirmation of eligibility and study entry form Version 2.0 5-Jul-2016

Page 1 of 5

CRF 01 – CONFIRMATION OF I	ELIGIBILITY AND STUDY ENTRY FORM
PIPS2 Site ID: Area:	Patient's Initials:
Patient ID:	Patient's DoB:
5. DATE WRITTEN CONSENT was obtained	ed:
	D D M M Y Y Y
6. CONFIRMATION OF ELIGIBILITY:	
Is the patient eligible to take part in the study	? Yes 🗌 No 🗌
7. Please write the name of the study site	in the field below:
8. Date of assessment:	
	D D M M Y Y Y
9. Gender	
	Male
10.000	Don't want to tell
10. Age	years
11. Current location (Please tick one)	
Other , please specify:	 Hospital Inpatient Hospice Inpatient At home In hospice day unit In hospital outpatients In hospice outpatients In care home Other residential care Other

\frown	Completed by					Completed on										
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	Y	Y	γ					

PiPS2 CRF 01 Confirmation of eligibility and study entry form Version 2.0 5-Jul-2016

	CRF 01 – CONFIRM	ATION OF ELIGIBILITY	AND STUDY EN	
PIPS2	Site ID:	Area:	Patient's Initials:	
	Patient ID:		Patient's DoB:	D D M M Y Y Y
12. Primary t	umour (Please tick a	all that apply)		
	[[[[[[[[[[[[[[[[[[[Breast Lung Prostate Urological (bladder, Haematological Upper GI tract Lower GI tract Head and Neck Gynaecological Neurological Rare Tumour Group Other 		
13. Sites of r	netastases (Please	Unknown primary tick all that apply).		
		 Liver Lung Bone Brain Skin Nodal Adrenal Renal Malignant ascites Malignant pleural eff Other None Unknown 	iusion	

\frown	Completed by				Completed on									
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	γ	Y	Y	Υ			

PiPS2 CRF 01 Confirmation of eligibility and study entry form Version 2.0 5-Jul-2016

	CRF 0	1 – CONFIR	MATION	I OF E	LIGIBIL	ITY A		Y ENTI	RY FORM	
PIPS2	Site ID:			Area:]	Patient's Ini	tials:		
	Patient ID:						Patient's Do	в:	D D M M Y	Y Y Y
14. Is patient therapy w				our-di	rected 1	thera	ıpy (or ha	is stop	oped receiving	such
									Yes 🗌	No 🗆
15. If 'YES' in	14 plea	ase specif	iy which	type	of treat	tmen	t (Please	tick all	that apply).	
			Ch	emoth	nerapy					
			🗌 Ra	diothe	erapy					
			🗌 Ho	rmone	e therap	у				
			🗌 Ot	her tu	mour dir	recte	d therapy	(e.g. ir	mmunotherapy)	

Principal Investigator's Signature Statement I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately re'lects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log. Principal Investigator's Signature: Principal Investigator's Name: Date of Signature:

Once signed, no further changes can be made to this CRF without a signed data query form.

\frown	Completed by		_	Com	plete	ed or	1				
Priment [™] Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	γ	γ	γ

PiPS2 CRF 01 Confirmation of eligibility and study entry form Version 2.0 5-Jul-2016

PS2	Site ID:	Area:	Patient's Initials	:
	Patient ID:		Patient's DoB:	D D M M Y Y
	of Capacity Assessm	ent Under Mental		
Who is	decision in question; asking that the decision should be mad asking that capacity be assessed?	e?		*0
Assessment	Question	Tick your assessm	ent	Tick your assessment
	e an impairment or disturbance ir ning of mind or brain? (permaner ary).	the state of the	y relevant evider	ment is not present, record ice If NO the person s ed capable - assessment s
-			•□	<u>-</u>
undersi decision Avoid "What will this	Il possible help given is the person al tand (U) the information relevant to ? questions inviting yes or no answer do you think this decision means? s decision affect you? Why do you thin n needs to be made? "	b the able to understand infi views/evidence to sh s. Try understood it. How	ow they steps views/	e to understand info. Record taken to explain info and evidence why they did not stand it.
enougt you un Remen	ey able to retain (R) the information to make the decision? e.g. "Tell me derstand by?" ber they only need to retain long enough be sure they have understood.	what able to retain info, record		e to retain information, record elp given and evidence.
as part "What	y able to balance (B) or weigh the inform of the decision making process? will happen if you make this decision? open if you do not make this decision?	able to weigh informati	on, record unable evider	e to weigh info record
d) Are the	y able to communicate (C) the decision	? YES able to communicate evidence.	* NO NO vider vider	e to communicate, record
to any of 3	 If the answer to 2. is YES and the and a) a) - d) is NO then the person lacks can the term of te		decision can wait u	er the person has fluctuating intil capacity returns. If this is e in outcome below.
		Name, Role and Signature		
		Date://	(DD/MM/YYYY)	

Page 5 of 5

	CRF 02	2 – PATIENT SY	MPTOMS						
PIPS2	Site ID:		Area:		F	Patient's Ir	itials:		
	Patient ID:				F	Patient's D	oB: D	D M M	Y Y Y Y
If the patient in the require		acity ask the pat ation.	tient. Mar	k the ar	iswers	by tick	ing the a	ppropriate b	oox or filling
Once respon	dent has	tal Test Score correctly answe			the as	sessm	ent can s	top.	
MENTAL TEST			NAM ADDR	3.					
			HOSPI	TAL NO:	<u>D.0</u>	. <u>B.</u>			
Ten-point MENTA Score one point for	L TEST SCOF each correct o	RE Date mswer of assessment							
AGE must be correct									
TIME without look and correct to neare	ing at clock or st hour	watch,							
42 WEST STREET twice, ask patient to it has registered), an	repeat immed id test recall at	liately (to check t end of procedure					_		
RECOGNISE TWO ask: 'Who is that pe		nt at nurse and other, bes she/he do?					_		
YEAR Exact, except in Jar	uary when pre	evious year is OK							
NAME OF PLACE may ask type of pla		own							
DATE OF BIRTH exact									
START OF FIRST Exact year	WORLD WA	R							
NAME OF PRESE	NT MONARC	н					_		
	other prompts;	rds, may prompt patient may hesitate s (tests concentration)							
CHECK RECALL ADD comment if comood abnormal, e.p depressed – may ef	ommunication (. deaf, dyspha	or TOTAL							
Is the Abbre	viated N	lental Test Sco	ore			_	1	4	
] less th] greate	an 4 r or equal 4	
							- 0	•	
	Com	pleted by					Com	pleted on	

	completed by											
Priment" Clinical Trials Unit			1	D	D	M	M	Y	Y	Y	Y]
	Print Name	Signature						. []

PiPS2 CRF 02 Patient symptoms Version 2.0 6-Jul-2016

Area: Patient's Initials:
Patient's DoB: D M Y Y Y
last week have you lost your appetite?"
n respond "No", if patient is receiving artificial nutrition respond "No", if ot request food or swallow food when offered then respond "Yes".
🗌 Yes
🗌 No
e last week have you had difficulty swallowing?"
n "Yes". If patient has enteral feeding tube (NG, PEG or PEJ) then
Yes
🗌 No
ring the last week have you felt breathless at rest?"
breathing appears labored or rapid then respond "Yes".
Yes
🗌 No
ast week have you felt fatigued?"
n respond "Yes". If the patient is more drowsy, tired or fatigued than
Yes
🗌 No
ight in the last month? – "During the last month have you lost
or cannot answer and/or it is not possible to judge then answer "No".
☐ Yes
🗌 No

\frown	Completed by		Com	plete	ed or	ı				
Clinical Trials Unit	Print Name	Signature	D	D	Μ	Μ	Y	Y	Y	Y

PiPS2 CRF 02 Patient symptoms Version 2.0 6-Jul-2016

	CRF 02 – PATIENT SY	MPTOMS			
PIPS2	Site ID:	Area:	Patient's Initials:		
	Patient ID:		Patient's DoB:	D D M M	Y Y Y Y

Principal Investigator's Signature Statement

I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.

Principal Investigator's Signature:

Principal Investigator's Name:

Date of Signature:

Once signed, no further changes can be made to this CRF without a signed data query form.

\frown	`	Completed by		Con	nplet	ed or	ı				
	Priment" Clinical Trials Unit	Print Name	Signature	D	D	Μ	M	Y	Y	γ	Y

PiPS2 CRF 02 Patient symptoms Version 2.0 6-Jul-2016

	CRF 03 - CLINICAL ASSESSMENT	
PIPS2	Site ID: Area: Patient's Initials:	
	Patient D D M Y Y Y ID: Y	γ
Please tick the	e appropriate box or answer by entering the reading/ number as required.	
	lly apparent ascites present? from history, clinical examination or investigations	
	🗌 Yes	
	🗌 No	
	lly apparent peripheral oedema present? y pitting oedema of dependent areas	
	🗌 Yes	
	🗌 No	
3. Pulse:		
	— — — bpm	
4a. Is the p	— — bpm patient delirious? If in doubt, use CAM (see worksheet on page 2)	
4a. Is the p		
4a. Is the p	patient delirious? If in doubt, use CAM (see worksheet on page 2)	
	patient delirious? If in doubt, use CAM (see worksheet on page 2)	?
	patient delirious? If in doubt, use CAM (see worksheet on page 2)	?
	patient delirious? If in doubt, use CAM (see worksheet on page 2) Yes No ious ("Yes" in 4a.) is delirium considered to be caused by a single medication?	?
4b. If deliri 5. Oral intak	patient delirious? If in doubt, use CAM (see worksheet on page 2) Yes No ious ("Yes" in 4a.) is delirium considered to be caused by a single medication? Yes No Ke**: If patient has capacity ask: "During last week has your food intake been	
4b. If deliri 5. Oral intal ** If patients a	patient delirious? If in doubt, use CAM (see worksheet on page 2) Yes No ious ("Yes" in 4a.) is delirium considered to be caused by a single medication? Yes Ves No Ke**: If patient has capacity ask: "During last week has your food intake been are receiving total parental nutrition they are categorized as "normal" oral intake, educed" means reduced but more than mouthfuls; and "severely reduced" means	
4b. If deliri 5. Oral intak ** If patients a "moderately re	patient delirious? If in doubt, use CAM (see worksheet on page 2) Yes No ious ("Yes" in 4a.) is delirium considered to be caused by a single medication? Yes Ves No Ke**: If patient has capacity ask: "During last week has your food intake been are receiving total parental nutrition they are categorized as "normal" oral intake, educed" means reduced but more than mouthfuls; and "severely reduced" means	
4b. If deliri 5. Oral intak ** If patients a "moderately re	patient delirious? If in doubt, use CAM (see worksheet on page 2) Yes No ious ("Yes" in 4a.) is delirium considered to be caused by a single medication? Yes Yes No Ke**: If patient has capacity ask: "During last week has your food intake been are receiving total parental nutrition they are categorized as "normal" oral intake, educed" means reduced but more than mouthfuls; and "severely reduced" means ess.	

\frown	Completed by		Con	nplete	ed or	ı				
Clinical Trials Unit	Print Name	Signature	D	D	Μ	Μ	Y	Y	Y	Y

	CRF 03	- CLINICA	LASSES	SMEN	т								
IPS2	Site ID:		Are	ea:		Patie	ent's Initials:						
	Patient ID:					Patie	ent's DoB:	D	D	M	M Y	Y	Y Y
and yea	te: This workshe sustained attent r backwards. Th	ion is recomme is page can on	an alternative nded prior to	to the scoring, dentify	Short CA , such as delirium o M-S scori	M Questionna digit spans, o cases. <u>Please</u> ing system.	aire. Testing of lays of week,	forien or mo	nths o	f			
EVA	LUATOR:					DATE:							
I.	ACUTE ONSE	ET AND FLUC	TUATING C	OURS	<u>E_</u>			B	DX 1		_		
	a) Is there evi status from	dence of an a the patient's I		in mer	ntal	No	Yes	·					
	b) Did the (ab day, that is decrease in	tend to come		-		No	Yes	·					
П.		N											
	Did the patien example, bein keeping track	g easily distra	ctible or hav			No	Yes	i					
III.	DISORGANIZ		3										
	Was the patie							BO)X 2				
	such as rambi or illogical flow from subject to	v of ideas, or i			hing	No	Yes						
IV.	ALTERED LE	VEL OF CON	SCIOUSNES	SS									
	Overall, how v consciousnes		the patient's	s level (of								
	Alert	(normal)			-								
	Vigilant	(hyperalert)											
	-	ic (drowsy, ea		1)									
		(difficult to a											
	Coma	(unarousab	e)										
Do a	ny checks ap	pear in the ba	ox above?		L	No	Yes						
		nd at least on											

Box 2 is checked a diagnosis of delirium is suggested.

Confusion Assessment Method. Copyright 1988, 2003, Hospital Elder Life Program. Not to be reproduced without permission. Adapted from: Inouye SK, et al. Ann Intern Med.1990;113:941-8.

\frown	Completed by		Com	plet	ed or	ı				
Clinical Trials Unit	Print Name	Signature	D	D	Μ	Μ	Y	Y	Y	Υ

	CRF 03 - CLINICAL ASSESSMENT
PIPS2	Site ID: Area: Patient's Initials:
FIF JZ	
	ID: Patient's DoB: D D M M Y Y Y
6. ECOG pe	erformance status - Please circle the appropriate grade
Grade	Definition
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g. light housework, office work)
2	Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4	Completely disabled; cannot carry on any self-care, totally confined to bed or chair
	ld you rate this patient's overall health during the past week? e the appropriate grade
1	2 3 4 5 6 7
Very poo	r Excellent
8. Karnofsk	y Performance Scale (KPS) - Please circle the appropriate percentage
100%	Normal, no complaints, no signs of disease
90%	Capable of normal activity, few symptoms or signs of disease
80%	Normal activity with some difficulty, some symptoms or signs
70%	Caring for self, not capable of normal activity or work
60%	Requiring some help, can take care of most personal requirements
50%	Requires help often, requires frequent medical care
40%	Disabled, requires special care and help
30%	Severely disabled, hospital admission indicated but no risk of death
20%	Very ill, urgently requiring admission, requires supportive measures or treatment
10%	Moribund, rapidly progressive fatal disease processes
0%	Death

\frown	Completed by			Completed on									
	Print Name	Signature		D	D	Μ	Μ	Y	Y	Y	Υ		

	CRF	03 - CLINICAL ASSESSM	IENT		
PIPS	S2 Site ID:	Area:	Patient's	Initials:	
	Patient ID:		Patient's	DoB: D	M M Y Y Y
9. PPS -	- Please cir	cle appropriate percen	tage in column PPS	level	
VICTORI HOSPIC			Palliative	Performance	Scale (PPSv2) version 2
PPS Level	Ambulation	Activity & Evidence of Disease	Self-Care	Intake	Conscious Level
100%	Full	Normal activity & work No evidence of disease	Full	Normal	Full
90%	Full	Normal activity & work Some evidence of disease	Full	Normal	Full
80%	Full	Normal activity with Effort Some evidence of disease	Full	Normal or reduced	Full
70%	Reduced	Unable Normal Job/Work Significant disease	Full	Normal or reduced	Full
60%	Reduced	Unable hobby/house work Significant disease	Occasional assistance necessary	Normal or reduced	Full or Confusion
50%	Mainly Sit/Lie	Unable to do any work Extensive disease	Considerable assistance required	Normal or reduced	Full or Confusion
40%	Mainly in Bed	Unable to do most activity Extensive disease	Mainly assistance	Normal or reduced	Full or Drowsy +/- Confusion
30%	Totally Bed Bound	Unable to do any activity Extensive disease	Total Care	Normal or reduced	Full or Drowsy +/- Confusion
20%	Totally Bed Bound	Unable to do any activity Extensive disease	Total Care	Minimal to sips	Full or Drowsy +/- Confusion
10%	Totally Bed Bound	Unable to do any activity Extensive disease	Total Care	Mouth care only	Drowsy or Coma +/- Confusion
0%	Death	-	-	-	-
1. PPS soc 2. Begin at located. 'stronger t t	t the left column and read of These steps are repeated er' determinants and genera Example 1: A patient who is but who is otherwise fully o Example 2: A patient who b be at 50%), the score is 30 The patient may have norm	ding horizontally at each level to find a "best fit' for th bowmwards until the appropriate ambulation level is n until all five columns are covered before assigning th illy take precedence over others. spends the majority of the day sitting or lying down di onscious level with good intake would be scored at F has become paralyzed and quadriplegio requiring tou % because he or she would be otherwise totally bed al intake and fill conscious level.	eached, then read across to the next column and e actual PPS for that patient. In this way, Teffw ue to fatigue from advanced disease and require PS 50%. al care would be PPS 30%. Although this patient bound due to the disease or complication if it w	I downwards again until the activi ard' columns (columns to the left s considerable assistance to wall may be placed in a wheelchair (are not for caregivers providing to	of any specific column) are k even for short distances and perhaps seem initially to tal care including lift/transfer.
s 3. PPS soc 'best fit'	since he or she is not 'total ores are in 10% increment decision. Choosing a 'half	care.' s only. Sometimes, there are several columns easily -fit' value of PPS 45%, for example, is not correct. 1	placed at one level but one or two which seem	better at a higher or lower level.	One then needs to make a
4. PPS ma		oses. First, it is an excellent communication tool for ts and comparisons. Finally, it appears to have progr	nostic value.	evel. Second, it may have value in	n criteria for workload
		Convright © 20	001 Victoria Hospice Society		

\frown	Completed by					Completed on										
Clinical Trials Unit	Print Name	Signature		D	D	M	Μ	Y	Y	Y	Y					

	CRF 03 - CLINICAL AS	SSESSMENT							
PIPS2	Site ID:	Area:	Patient's Initials:						
	Patient ID:]	Patient's DoB:	D D	MM	Y	Υ	Υ	Y

Definition of Terms for PPS

is noted below, some of the terms have similar meanings with the differences being more readily apparent as one reads horizontally across each row to find an overall 'best fit' using all five columns

1. Ambulation

The items 'mainly sit/lie,' 'mainly in bed,' and 'totally bed bound' are clearly similar. The subtle differences are related to items in the self-care column. For example, 'totally bed 'bound' at PPS 30% is due to either profound weakness or paralysis such that the patient not only can't get out of bed but is also unable to do any self-care. The difference between 'sit/lie' and 'bed' is proportionate to the amount of time the patient is able to sit up vs need to lie down.

'Reduced ambulation' is located at the PPS 70% and PPS 60% level. By using the adjacent column, the reduction of ambulation is tied to inability to carry out their normal job, work occupation or some hobbies or housework activities. The person is still able to walk and transfer on their own but at PPS 60% needs occasional assistance

2. Activity & Extent of disease

Some, 'significant,' and 'extensive' disease refer to physical and investigative evidence which shows degrees of progression. For example in breast cancer, a local recurrence would imply 'some' disease, one or two metastases in the lung or bone would imply 'significant' disease, whereas multiple metastases in lung, bone, liver, brain, hypercalcemia or other major complications would be 'extensive' disease. The extent may also refer to progression of disease despite active treatments. Using PPS in AIDS, 'some' may mean the shift from HIV to AIDS, 'significant' miplies progression in physical decline, new or difficult symptoms and laboratory findings with low counts. "Extensive' disease one errous serious complications with or without continuation of active antiretrovirals, antibiotics, etc.

The above extent of disease is also judged in context with the ability to maintain one's work and hobbies or activities. Decline in activity may mean the person still plays golf but reduces from playing 18 holes to 9 holes, or just a par 3, or to backyard putting. People who enjoy walking will gradually reduce the distance covered, although they may continue trying, sometimes even close to death (eg. trying to walk the halls).

3. Self-Care

Occasional assistance' means that most of the time patients are able to transfer out of bed, walk, wash, toilet and eat by their own means, but that on occasion (perhaps once daily or a few times weekly) they require minor assistance.

'Considerable assistance' means that regularly every day the patient needs help, usually by one person, to do some of the activities noted above. For example, the person needs p to get to the bathroom but is then able to brush his or her teeth or wash at least hands and face. Food will often need to be cut into each bib sizes but the patient is then able to each of his or her own accord.

'Mainly assistance' is a further extension of 'considerable.' Using the above example, the patient now needs help getting up but also needs assistance washing his face and shaving, but can usually eat with minimal or no help. This may fluctuate according to fatigue during the day.

'Total care' means that the patient is completely unable to eat without help, toilet or do any self-care. Depending on the clinical situation, the patient may or may not be able to chew and swallow food once prepared and fed to him or her.

4. Intake

Changes in intake are quite obvious with 'normal intake' referring to the person's usual eating habits while healthy. 'Reduced' means any reduction from that and is highly variable according to the unique individual circumstances. 'Minimal' refers to very small amounts, usually pureed or liquid, which are well below nutritional sustenance.

5. Conscious Level

Full consciousness' implies full alertness and orientation with good cognitive abilities in various domains of thinking, memory, etc. 'Confusion' is used to denote presence of either delirium or dementia and is a reduced level of consciousness. It may be mild, moderate or severe with multiple possible etiologies. 'Drowsiness' implies either fatigue, drug side effects, delirium or closeness to death and is sometimes included in the term stupor. 'Coma' in this context is the absence of response to verbal or physical stimuli, some reflexes may or may not remain. The depth of coma may fluctuate throughout a 24 hour period.

© Copyright Notice. rmance Scale version 2 (PPSv2) tool is copyright to Victoria Hospice Society and replaces the first PPS published in 1996 [J Pall Care 9(4): 26-32]. It cannot be altered or used in any way other than as intended and described here. Programs may use PPSv2 with appropriate recognition. Available in electronic PDF formal by request to https://victoriahospice.org/reprint-and-use-information/ Correspondence should be sent to the Director of Education & Research, Victoria Hospice Society, 1952 Bay Street, Victoria, BC, V8R 1J8, Canada The Palliative Perfo

	Completed by	Completed on										
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	Y	Y	Y	

CF	CRF 03 - CLINICAL ASSESSMENT									
PIPS2 Site	ID:	Area:	Patient's Initials:							
Pat ID:	ent		Patient's DoB:	D D M M Y Y Y Y						
 10. Time to terminal disease Time between diagnosis of cancer and date at which cancer became incurable (to the nearest month). The time at which the cancer became incurable is either the time at which it is deemed to be inoperable or becomes metastatic, whichever is the sooner. If no information is available then please estimate the time to terminal disease by entering the median time between diagnosis and today's date. 										
10a. Please indicate if the "time to terminal disease" has been calculated:										
i) based on discussion with patient, staff and/or from review of notes										
		or								
ii) by estim	ation only									
	d time to terminal d an one month then		from diagnosis	s score 0, if time						
				months						
Principal Inves	tigator's Signatu	re Statement								
I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.										
Principal Investigato	r's Signature:									
Principal Investigato	r's Name:		Date of S	Signature:						

Once signed, no further changes can be made to this CRF without a signed data query form.

\frown	Completed by				Completed on										
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	Y	γ	Υ				

	CRF 04	- BLOO	D RESU	LTS			
PIPS2	Site ID:			Area:		Patient's Initials:	
	Patient ID:					Patient's DoB:	D D M M Y Y Y Y
Blood result	s (from n	ne <mark>dica</mark> l r	notes o	r <mark>electr</mark>	onic patie	nt record)	
scheduled to	have a b	lood test	within 7	2 hours	of study e	nrolment, these	n still in lab) or are blood tests should be results recorded here.
For patients v	vith capa	<u>city</u> blood	l results	must b	e recorded		
1. White blo	ood cour	nt:					
							<u> </u>
2. Lymphod	cyte cou	nt (pleas	e enter	as 10%	L or if not	available as %):
							— — · — — ×10 ⁹ /L
							`%
3. Neutroph	nil count						
4. Platelet o							<u> </u>
4. Platelet C	ount.						
5. Urea:							<u> </u>
							— — [·] — mmol/L
6. Albumin:							
							— — q/L
7. Alkaline p	hosphat	ase:					
							<u> </u>
8. Alanine tr	ansamin	ase					
							— — — U/L
9. C reactive	e protein						
							<u> </u>
10. Lactate I	Dehydro	genase					
							<u> </u>

Deimant	Completed by		Completed on									
Clinical Trials Unit	Print Name	Signature										

PiPS2 CRF 04 Blood results Version 1.0 4-Jul-2016

	CRF 04 - BLOOD	RESULTS									
PIPS2	Site ID:	Area:	Patient's Initials:								
	Patient ID:		Patient's DoB:	D	D	М	M	Y	Y	Y	Y

Principal Investigator's Signature Statement

I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.

Principal Investigator's Signature:

Principal Investigator's Name:

Date of Signature:

Once signed, no further changes can be made to this CRF without a signed data query form.

0	Completed by	Completed by					Completed on								
Clinical Trials Unit	Print Name	Signature		D	D	M	M	Ý	Ŷ	Y	Y				

PiPS2 CRF 04 Blood results Version 1.0 4-Jul-2016

	CRF 05 – DOCTOR PRE	DICTION OF SURVIV	/AL	
PIPS2	Site ID:	Area:	Patient's Initials:	
	Patient ID:		Patient's DoB:	D D M M Y Y Y Y

To be filled in by the doctor

Please answer by ticking the appropriate box or filling in the required information.

1. Please enter the date when this form was completed/ the estimate obtained:								
	D D M M Y Y Y							
2. What is your speciality?								
Palliative med	dicine							
Oncology								
Other								
Other, please specify:								
3. Please state your professional grade:								
Foundation								
Core Medical Trainee								
Specialist Trainee								
Consultant								
Other								
Other, please specify:								
4. How many years have you been working as	a doctor since you qualified?							
years								
5. How many years have you been working in	palliative care?							
years								
6. Please state your gender:								
🗌 Female								
🗌 Male								
Don't wish to answer								

	Completed by					Completed on									
	Print Name	Signature		D	D	Μ	Μ	Y	Y	γ	Y				

	CRF 05 - D	OCTOR PREDICTION OF SURVI	VAL		
PIPS2	Site ID:	Area:	Patient's	Initials:	
	Patient ID:		Patient's	DoB:	D D M M Y Y Y Y
7. How old a	re you?				
	_	years			Don't wish to answer
8. How long	have you ha	d a relationship with the pati	ent? (ticl	k only	one box)
		Less than one week			
		Less than one month			
		Less than three months			
		Three months or more			
		Never met patient			
9. When did	you last ass	ess the patient? (tick only one	box)		
		Today			
		Within the last three days			
		Within the last week			
		Within the last month			
		Over one month ago			
		Never met patient			
10. What is y (tick only		mate estimate of the length o	f this pa	tient's	s survival?
		"Days" = 0 – 13 days			
		"Weeks" = 14 – 55 days (2 –	7 weeks)		
		"Months+" = 56 days or great	er (i.e. 8	weeks	or two months) or more

\cap	Completed by			Completed on									
Clinical Trials Unit	Print Name	Signature		D	D		M	M	γ	Y	Ŷ	Y	

	CRF 0	5 – DOCTOR PREDICTIO	ON OF SURVIV	/AL	
PIPS2	Site ID:	Area:		Patient's Initials:	
	Patient ID:			Patient's DoB:	D D M M Y Y Y
11. What is y	your mo	re specific estimate of	f this patient'	's survival? (†	tick only one box)
		1 week or less			
		2 weeks			
		3 weeks			
		4 weeks			
		5 weeks			
		6 weeks			
		7 - 8 weeks			
		9 - 10 weeks			
		11 - 12 weeks			
		more than 12 we	eks		
12. Please s	tate the	estimated probability	of this natier	nt's survival f	for all of the time periods

listed below.

100% probability means that you think the patient is certain to survive as long as the specified time period, 50% probability means that you think there is an equal probability that they may or may not survive, and 0% probability indicates that you are certain that they will not survive as long as the period specified.

The probability of survival should decrease or stay the same as one considers longer and longer time periods. Thus if, for example, you consider that the patient has a 70% chance of surviving for 1 day then their probability of surviving 3, 7, 15, 30 or 60 days must be 70% or lower.

1 day	%	
3 days	%	
7 days	%	
15 days	%	
30 days	%	
60 days	%	
h		

\frown	Completed by			Completed on								
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	Y	Y	Y	

CRF 05 – DOCTOR PREDICTION OF SURVIVAL								
PIPS2	Site ID:	Area:	Patient's Initials:					
	Patient ID:		Patient's DoB:	DD	MM	Y Y	Y Y	

Principal Investigator's Signature Statement									
I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.									
Principal Investigator's Signature:	Principal Investigator's Signature:								
Principal Investigator's Name:	Date of Signature:								

Once signed, no further changes can be made to this CRF without a signed data query form.

\frown	Completed by		Completed on									
Clinical Trials Unit	Print Name	Signature		D	D	M	Μ	γ	Y	Y	Υ	

PIPS2	Site ID: Area:	Patient's Initials:							
	Patient ID:	Patient's DoB:	D D	Μ	Μ	γ	Y	Y	Y

To be filled in by the nurse

Please answer by ticking the appropriate box or filling in the required information.

1. Please enter the date when this form was completed/ the estimate obtained:
D D M M Y Y Y
2. What is your speciality?
Palliative care
Oncology
Other
Other, please specify:
3. Please state your professional grade:
Band 5
Band 6
Band 7
Band 8
Nurse consultant
Other
Other, please specify:
4. How many years have you been working as a nurse since you qualified?
years
5. How many years have you been working in palliative care?
years
6. Please state your gender:
Female
Male
Don't wish to answer

\frown	Completed by			Completed on									
Priment [™] Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Υ	Y	γ	Y		

	CRF 06 - NU	JRSE PREDICTION OF SURVIV	AL		
PIPS2	Site ID:	Area:	Patient's	s Initials:	
	Patient ID:		Patient	s DoB:	D D M M Y Y Y
7. How old a	re you?				
		years			Don't wish to answer
8. How long	have you ha	d a relationship with the pation	ent? (tic	k only	one box)
		Less than one week			
		Less than one month			
		Less than three months			
		Three months or more			
		Never met patient			
9. When did	you last asse	ess the patient? (tick only one	box)		
		Today			
		Within the last three days			
		Within the last week			
		Within the last month			
		Over one month ago			
		Never met patient			
10. What is y (tick only		mate estimate of the length o	f this p	atient'	s survival?
		"Days" = 0 – 13 days			
		"Weeks" = 14 – 55 days (2 –	7 weeks	5)	
		"Months+" = 56 days or great	er <mark>(</mark> i. e.	8 week	s or two months or more)

\frown	Completed by		Completed on								
Clinical Trials Unit	Print Name	Signature		D	D	М	M	Y	γ	Y	γ

	CRF 0	- NURSE PREDICTIO	N OF SURVIV	AL	
PIPS2	Site ID:	Area:		Patient's Initials:	
	Patient			Patient's DoB:	D D M M Y Y Y Y
		··· ·· ·			
11. What is	your mo	re specific estimate o	of this patien	t's survival? (tick only one box)
		1 week or less			
		2 weeks			
		3 weeks			
		4 weeks			
		5 weeks			
		6 weeks			
		7 - 8 weeks			
		9 - 10 weeks			
		11 - 12 weeks			
		🔲 more than 12 w	eeks		
12. Please s listed be		estimated probability	of this patie	ent's survival	for all of the time periods
period, 50% p survive, and 0 period specifi The probabilit time periods.	probability D% proba ed. ty of surv Thus if, f	y means that you think bility indicates that you ival should decrease of	there is an e u are certain f or stay the sar der that the p	qual probability that they will no me as one con atient has a 70	s long as the specified time y that they may or may not ot survive as long as the siders longer ard longer 0% chance of surviving for 70% or lower.
		1 day		%	
		3 days		%	
		7 days		%	
		15 days		%	
		30 days		%	
		60 days		%	

\frown	Completed by		Completed on										
Clinical Trials Unit	Print Name	Signature		D	D	Μ	Μ	Y	Y	Y	Y		

PiPS2 CRF 06 Nurse prediction of survival Version 2.0 11-Jul--2016

Page 3 of 4

	CRF 06 - NURSE P	REDICTION OF SU	RVIVAL								
PIPS2	Site ID:	Area:	Patient's Initials:								
	Patient ID:		Patient's DoB:	D	D	M	M	Y	γ	Y	Ŷ

Principal Investigator's Signature Statement

I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.

Principal Investigator's Signature:

Principal Investigator's Name:	Date of Signature:

Once signed, no further changes can be made to this CRF without a signed data query form.

\cap	Completed by		Con	plet	ed or	1				
Clinical Trials Unit	Print Name	Signature	D	D	M	Μ	Y	Ŷ	Y	Y

	CRF 07 - MDT	OF SURVIVAL		
PIPS2	Site ID:	Area:	Patient's Initials:	
	Patient ID:		Patient's DoB:	D D M M Y Y Y
survival	,	nurse independently g to question 10 on CRF	•••	proximate length of
			🗌 Yes	s – go to 2.
			No No	– go to 3 and 3a.

2. If the answer to question 1 is "yes" (doctor and nurse independently agree on approximate length of survival), please tick below the agreed MDT estimate.

□ "Days" = 0 – 13 days

□ "Weeks" = 14 – 55 days (2 – 7 weeks)

"Months+" = 56 days or greater (i. e. 8 weeks or two months or more)

\sim	Completed by	Completed on	
	Print Name	Signature	D D M M Y Y Y Y

PiPS2 CRF 07 MDT estimate of survival Version 1.0 4-Jul-2016

	CRF 07 - MDT OF	SURVIVAL									
PIPS2	Site ID:	Area:	Patient's Initials:								
	Patient ID:		Patient's DoB:	D	D	M	M	Y	γ	Y	Y

Principal Investigator's Signature Statement

I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.

Principal Investigator's Signature:

Principal Investigator's Name:	Date of Signature:

Once signed, no further changes can be made to this CRF without a signed data query form.

\cap	Completed by	Completed				ed or	t on								
Clinical Trials Unit	Print Name	Signature		D	D	M	M	Y	Y	Y	Y				

PiPS2 CRF 07 MDT estimate of survival Version 1.0 4-Jul-2016

Priment [™]		erse Event Rep on-CTIMP stud	9		
Clinical Trials Unit	,	V1.0 12/02/201	6		Page 1 of 2
Trial Number:	Patient's Initials:	5	Date of dd	m m	у у у у
Site:		Responsible Clinician:			
1. Type of report 1 = First 2 = Follow Up If follow up specify number 4. Height cm	2. Trial Arm N/A (Non-ini 5. Weight	erventional)	3. Sex 1=Male 2=Fema 6. Body Su Area	ale	• m²
7. Why was the event set 1 = Resulted in Death 2 = Life-threatening 3 = Required inpatient h Prolongation of exist 4 = Persistent or signific 5 = Congenital anomaly 6 = Other	nospitalisation or ting hospitalisation cant disability/incapacit	y 5=	e did SAE take p Hospital Out-patient clinic Home Nursing Home Other ther specify:	lace?	
Details of SAE					12 Data washed
9. Main diagnosis/symptom	10. Severity 1=Mild 2=Moderate 3=Severe	11. Date of onset	t 12. SAE Status 1= Resolved 2= Resolved with s 3= Unresolved 4= Worsened 5= Fatal 6= Not assessable		13. Date resolved
Study Intervention (If your study is no	n-interventional pla	pase move to 'Oth	er treatments' be	low.	
14.Intervention 15.Date of first 16.Actu			9.was the event		on taken due to SAE

14.Intervention	administration of intervention	given at most recent	most recent administration of intervention		0=No 1=Yes	0=None 1=intervention stopped 2=Intervention ellayed 3=Intervention emended 4= Other (pleast describe)
	dd/mm/yyyy		dd/mm/yyyy			
N/A	N/A	N/A	N/A	N/A	N/A	N/A

21.Treatment Give generic name	22.Total Daily Dose	23.Route 1= Oral 2= Intravenous 3= Subcutaneous 4= Other	24.Start Date	25.Ongoing 0=No 1=Yes	26.End Date	27.Causal relationship to SAE 1 = Definitely 2 = Probably 3 = Possibly 4 = Unlikely 5 = Not related	28.Action taken due to SAE 0=None 1=Dose reduction 2=Treatment delayed 3=Treatment reductio & delayed 4= Treatment stopped
			dd/mm/yyyy		dd/mm/yyyy	6= No assessable	4= meanient stopped
							_

Signed by:	Printed Name:	Date Completed:					
		d d m m y y y					
-							
For office use only:							
Date form entered onto database	dd - mm - yyyy	Initials of data enterer:					

Priment™	Serious Adverse Event Reporting F Non-CTIMP studies	orm
Clinical Trials Unit	V1.0 12/02/2016	Page 2 of 2
Trial Number:	Patient's Date of Initials:	d d m m y y y y
Site	Responsible Clinician:	
Country: UK		

29. Describe the serious adverse event (include manifestation & progression of event, any treatments given in response to the event and any relevant tests carried out e.g. WBC, neutrophil count. Continue on a separate sheet if necessary).									
Diagnostic Tests:									
30. Test name									
31. Date									
32. Normal range									
33. Result (+ units)									

	·
ne aware of this event d d	m m y y y y

Signed by:	Printed Name:						
Contact Telephone:	Date Completed:						
Please email to primentsafetyreport@ucl.ac.uk with 24 hours of becoming aware of the event							

Priment Use ONLY SUSAR:7 day SUSAR:15 day Event No Date sent to REC Form checked and Ready to file Priment Staff Signature

For office use only:

Date form entered onto database : dd - mm - yyyy

Initials of data enterer:

	CRF 09 - WITHD	RAWAL		
PIPS2	Site ID:	Area:	Patient's Initials:	
	Patient ID:		Patient's DoB:	D D M M Y Y Y
1. Has the p	patient withdrawn	n from the study?		
			🗌 Yes	– go to 2 and 3
			🗌 No	

2. Please give reason why the patient has withdrawn from the study:								
Withdrawn consent								
Other, please specify:								

3. Please give the date of withdrawal:									
D D M M Y Y Y									
Principal Investigator's Signature Statement									
I have reviewed the CRFs and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this participant. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log.									
Principal Investigator's Signature:									
Date of Signature:									

Once signed, no further changes can be made to this CRF without a signed data query form.

\cap	Completed by		Completed on								
Clinical Trials Unit	Print Name	Signature		D	D	M	Μ	Ŷ	Y	Y	Y

PiPS2 CRF 09 Withdrawal Version 2.0 14-Jul-2016